Titlebook: Stroke Revisited: Dyslipidemia in Stroke; Seung-Hoon Lee,Min Kyoung Kang Book 2021 The Editor(s) (if applicable) and The Author(s), under

裹住

Role of Dyslipidemia in Atherosclerosisines and chemokines (TNF-α, IL-1β, IL-6, MCP-1), and millions of different antigens. This makes the development of atherosclerosis very challenging. In addition to the development of myocardial infarctions, atherosclerosis is also associated with peripheral artery disease. This pathological conditio

晚间

Effects of Dyslipidemia on the Cerebral Vesselsscle cells, and their debris are cumulated under the endothelial cell lining. Then, the cumulated products form lipid cores, and these eventually form atheromatous plaques. High blood cholesterol, excluding HDL, eventually causes arteriosclerosis of blood vessels to narrow the diameter of the vessel

专横

Impact of Dyslipidemia on Ischemic Stroke-scale clinical trials in stroke patients..Triglyceride (TG) level is high in many clinical situations and has influenced adverse cardiovascular diseases. Despite managing LDL-C adequately, residual risks still remain. Therefore, we must closely observe TGs for patients who are at high risk of ather

残酷的地方

Dyslipidemia and Hemorrhagic Stroke in primary stroke prevention. In secondary stroke prevention, the risk of ICH showed a nonsignificant trend for statin therapy and was significantly associated with lipid-lowering therapy. The risk of ICH from statin or lipid-lowering therapy is offset by the prevention of ischemic stroke and subst

STAT

Clinical Biomarkers of Dyslipidemiarly prediction and drug development. Here, we reviewed the use of nontraditional lipid biomarkers including apolipoproteins and lipid peroxidation and discussed the role of metabolomics and lipidomics in improving stroke risk evaluation and monitoring the drug effects.

弯腰

FLIC

Statinsding Rosuvastatin, Atorvastatin, Simvastatin, Fluvastatin, Pravastatin, Lovastatin, and Pitavastatin. The key pharmacological properties of each statin are slightly different according to their solubility and chemical features. As for their implications on stroke trials, the association between pre-

Hemodialysis

Ezetimibelowering effects of ezetimibe, many clinicians are still not convinced of the clinical benefits of ezetimibe. This chapter aims to elucidate the developmental history, pharmacokinetic profiles, mechanisms of action, therapeutic adjustment for practical use, and clinical trial data that may support t

instate

Fibrate and Niacin based on clinical trials. Also, recent studies have shown neutral results in that the application of combined niacin and statins can prevent stroke and cardiovascular diseases. Hence, in the future, the effect of fibrates and niacin in decreasing the residual risk of stroke and cardiovascular disea

树上结蜜糖